Help protect your baby starting with their first breath.
Pfizer’s ABRYSVO is the only maternal RSV vaccine given during weeks 32 through 36 of pregnancy to help protect newborns against RSV from birth through 6 months.
ABRYSVO is a CDC-recommended vaccine
The CDC recommends ABRYSVO if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). There are areas in the U.S., including southern FL, AK, HI, and the U.S. territories, where RSV does not follow typical seasonal patterns and the recommended months for maternal vaccination may differ.
Help protect infants against the risk of RSV from birth
RSV is a highly contagious respiratory virus that can make your baby sick, especially if they’re under 6 months old.
- Nearly 50% of all RSV hospitalizations during the first year occur during the first 3 months of life.
- 75-80% of hospitalizations due to RSV happened during the first 6 months of life.
Pregnant women should receive Pfizer’s ABRYSVO during weeks 32 through 36 of pregnancy
The CDC recommends ABRYSVO if you are 32 to 36 weeks pregnant during September through January (in most of the United States). In some states, the recommended months for maternal vaccination may differ.
Take the first step in protecting your baby against RSV by seeing if you’re eligible.
How does maternal immunization with ABRYSVO protect your baby?
Maternal immunization with ABRYSVO is a choice pregnant women can make to help protect their babies.
- Maternal immunization with ABRYSVO refers to the process of vaccinating a pregnant woman so protective antibodies can be passed to the baby through the placenta before birth.
- During pregnancy, your body naturally passes on antibodies that help protect your baby against bacteria and viruses, like RSV, in the first few months of life, before they’re old enough to develop their own protection. Pfizer’s ABRYSVO helps your body create RSV antibodies that are passed to your unborn baby to help protect them from birth through 6 months.
- Eligible pregnant women can choose to receive Pfizer’s RSV vaccine ABRYSVO between 32 and 36 weeks of pregnancy so that their baby doesn’t have to receive a shot themselves after birth.
Pfizer's vaccine ABRYSVO helps protect your baby against RSV.
ABRYSVO was studied in a clinical trial including over 7,000 pregnant women and their babies, where 3,495 pregnant women received ABRYSVO and 3,480 received a placebo. The study showed ABRYSVO reduced the risk of severe RSV by 69% compared with placebo in infants measured at 6 months after birth.
Most common side effects of Pfizer’s ABRYSVO
Pfizer’s ABRYSVO is given between weeks 32 through 36 of pregnancy
ABRYSVO was studied in clinical trials including over 7,000 pregnant women and their babies, where 3,797 pregnant women received ABRYSVO and 3,675 received a placebo.
View full prescribing information
Get to know more about RSV and protecting your baby with Pfizer’s ABRYSVO
Cost and coverage*
Pfizer’s ABRYSVO may be made available by certain insurance plans at no cost in accordance with the Inflation Reduction Act.*
Talk to your doctor or pharmacist to see if Pfizer’s ABRYSVO is covered under your insurance plan. Additional savings and support options may be available at Pfizer RxPathways®.
Learn more about cost and coverage
*This information is provided for informational purposes only. Accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. Pfizer and its agents make no guarantee regarding reimbursement for any service or item. Certain vaccines may be covered or available at lower out-of-pocket costs in Medicare Part D, Medicaid, the Children’s Health Insurance Program, or other consumer plans through the Inflation Reduction Act. Coverage may vary based on the vaccine and the insurance plan. For more information, visit cms.gov.
Ask About Pfizer’s ABRYSVO
Pregnancy is a time when you may have a lot of questions for your doctor. Start the conversation about RSV and Pfizer’s ABRYSVO today.
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants. The risk of your baby being admitted to hospital with RSV is 16x higher than the flu. RSV is very easily spread to people in hospitals, at home, and in nurseries. The largest group of babies requiring hospitalization due to RSV are those aged less than 6 months old.
Other things that can put infants at risk are:
- Are born prematurely
- Are up to 12 months old, especially those 6 months and younger
- Are less than 2 years old with chronic lung disease or heart disease present from birth
- Have weakened immune systems
- Have neuromuscular disorders, including difficulty swallowing or clearing mucus from the chest
The CDC recommends ABRYSVO if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). However, there are areas in the U.S., including southern Florida, Alaska, Hawaii, and the U.S. territories, where RSV does not follow the typical seasonal patterns and the recommended months for maternal vaccination may differ.
Talk to your OB-GYN to learn more about how to protect your baby against RSV during their first RSV season and whether ABRYSVO is right for you.
Pregnant women who received ABRYSVO most commonly reported pain at the injection site, headache, muscle pain and nausea.
Jaundice, also known as temporary yellowing of the eyes and skin, was seen in 7.2% of infants in the ABRYSVO group and 6.7% in the placebo group.
Low birth weight was observed in 5.1% of infants in the ABRYSVO group versus 4.4% in the placebo group.
- Am I eligible to receive ABRYSVO?
- Is it safe for my baby if I get vaccinated while pregnant?
- Is it safe for me?
- How much protection can my baby get if I receive a vaccine while pregnant?
- What vaccination options should I know about?
- When during my pregnancy should I receive a vaccine?
- If I’m uncomfortable with getting vaccinated while pregnant, what are my other options?